Frontier Medicines Corporation (Frontier), a clinical-stage, AI-powered precision medicines company that discovers and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, a precision medicine company focused on the discovery and development of best-in-class targeted medicines, today announced that the first ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
RLY-2608’s pan-mutant inhibition has the potential to address over 100,000 patients per year in the U.S. The data presented at the conference show that in preclinical models, RLY-2608 preferentially ...
Novartis announced that it has agreed to acquire a next-generation PI3Kα inhibitor program from Synnovation Therapeutics in a deal valued at $2 billion upfront, with up to $1 billion in additional ...
Relay Therapeutics’ Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets ...
Treatment with RLY-2608 plus fulvestrant appears well tolerated among patients with PI3Kα-mutated breast cancer in the ReDiscover trial. Combining the investigational PI3Kα inhibitor RLY-2608 with ...
EMERYVILLE, Calif., April 10, 2023 /PRNewswire/ -- Totus Medicines, a clinical stage biotechnology company fueled by its breakthrough Accel ™ platform, announced it will be presenting four posters at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results